American Association for Clinical Chemistry (AACC) 2022 Virtual Conference
Wed, Nov 30
|Virtual
Spatial Molecular Profiling of the Cancer Tissue Microenvironment: A Revolution in Biomarker Diagnostics
Time & Location
Nov 30, 2022, 12:30 PM – 5:30 PM
Virtual
About the event
Open to Public
Event Info Email
RSVP - nboddie@gmu.edu
The field of tissue spatial molecular profiling has reached a high level of sophistication. It offers a rich set of technologies, software, and protocols of interest to the American Association for Clinical Chemistry membership members.
Join us for this collaborative half-day symposium to learn about the latest cancer biomarker discoveries using these new tools, and have access to expert guidelines, standard protocols, and technology choices for their own specific intended uses.
AGENDA
12:30 to 12:50 PM - Â Introduction/Opening Remarks
Dr. Liotta, George Mason University
Spatial Tissue Molecular Profiling
12:50 to 1:20 PM
Dr. Eva Hedlund, Karolinska Institute
LCM-Seq, a novel spatially anchored, extraction-free method for single and multicellular RNA-seq in tissue
1:20 to 1:50 PM
Dr. Kevin Janes, University of Virginia
10cRNAseq with stochastic profiling for inferred single-cell expression in tissue
1:50 to 2:20 PM
Dr. Robert West, Stanford University
Spatial transcriptomics in FFPE clinical archival tissues with novel Smart-35eq method
2:20 to 2:30 PM - Â BREAK
2:30 to 3:00 PM
Dr. Emanuel Petricoin, George Mason University
Spatial phospho-proteomic profiling of breast cancer predicts the likelihood that an individual patient's HER2postivie tumor will respond by complete pathologic response(PCR) to neoadjuvant HER2 therapies
3:00 to 3:30 PM
Dr. Michael T. Eadon, Indiana University Health Medical Center
Cellular and molecular interrogation of kidney biopsy specimens.
3:30 to 4:00 PM
Dr. R.M.A. Heeren, Maastrich University Netherlands
Combining LCM and imaging MS to achieve in-depth tissue multi-omics
4:00 to 4:30 PM
Dr. Shawn M. Davidson, Princeton University
Metabolomic spatial tissue profiling using imaging mass spectrometry
4:30 to 5:00 PM
Dr. Tom Conrads, INOVA Schar Cancer Institute
Intratumor Proteogenomic Heterogeneity Revealed by Multiregion Sampling in a High-Grade Serous Ovarian Tumor Specimen
5:00 to 5:30 PM - Â Closing Remarks
Dr. Laura Esserman, UCSF
Interrogating the breast cancer microenvironment: driving therapeutic discovery using innovative clinical trial designs